| Literature DB >> 27231919 |
Flore Dagorn1, Aurélie Couzinet-Mossion2, Melha Kendel3, Peter G Beninger4, Vony Rabesaotra5, Gilles Barnathan6, Gaëtane Wielgosz-Collin7.
Abstract
Economic exploitation is one means to offset the cost of controlling invasive species, such as the introduced Pacific oyster (Crassostrea gigas Thunberg) on the French Atlantic coast. Total lipid and phospholipid (PL) fatty acids (FAs) and sterols were examined in an invasive population of C. gigas in Bourgneuf Bay, France, over four successive seasons, with a view to identify possible sources of exploitable substances. The total lipid level (% dry weight) varied from 7.1% (winter) to 8.6% (spring). Of this, PLs accounted for 28.1% (spring) to 50.4% (winter). Phosphatidylcholine was the dominant PL throughout the year (up to 74% of total PLs in winter). Plasmalogens were identified throughout the year as a series of eleven dimethylacetals (DMAs) with chain lengths between C16 and C20 (up to 14.5% of PL FAs + DMAs in winter). Thirty-seven FAs were identified in the PL FAs. Eicosapentaenoic acid (20:5n-3 EPA/7.53% to 14.5%) and docosahexaenoic acid (22:6n-3 DHA/5.51% to 9.5%) were the dominant polyunsaturated FAs in all seasons. Two non-methylene-interrupted dienoic (NMID) FAs were identified in all seasons: 7,13-docosadienoic and 7,15-docosadienoic acids, the latter being present at relatively high levels (up to 9.6% in winter). Twenty free sterols were identified, including cholesterol at 29.9% of the sterol mixture and about 33% of phytosterols. C. gigas tissues thus contained exploitable lipids for health benefits or as a potential source of high-quality commercial lecithin.Entities:
Keywords: Crassostrea gigas; bivalve; fatty acids; health and nutrition; mollusc; non-methylene interrupted fatty acids; phospholipids; plasmalogens; seasonal variations
Mesh:
Substances:
Year: 2016 PMID: 27231919 PMCID: PMC4926063 DOI: 10.3390/md14060104
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Seasonal total tissue lipid content (TL) (% DW) and lipid class composition (% TL) of Crassostrea gigas. Values are the mean of three replicates (mean ± standard deviation).
| Collection Season | Total Lipids (% DW) | Neutral Lipids (% TL) | Glycolipids (% TL) | Phospholipids (% TL) |
|---|---|---|---|---|
| Winter (January) | 7.1 ± 0.5 | 40 ± 1 | 9 ± 2 | 50.4 ± 0.4 |
| Spring (April) | 8.6 ± 0.2 | 64.5 ± 0.7 | 7.4 ± 0.7 | 28.1 ± 0.9 |
| Summer (July) | 7.9 ± 0.1 | 39.3 ± 0.4 | 12.4 ± 0.4 | 48.0 ± 0.5 |
| Autumn (November) | 8.1 ± 0.4 | 50.3 ± 0.9 | 10.4 ± 0.8 | 39.3 ± 0.4 |
Seasonal phospholipid class composition of Crassostrea gigas (% phospholipids). Values are the mean of three replicates (mean ± standard deviation).
| Phospholipid Class | Winter | Spring | Summer | Autumn |
|---|---|---|---|---|
| Cardiolipin | 6.8 ± 0.3 | 10.7 ± 0.3 | 7.2 ± 0.6 | 4.9 ± 0.5 |
| Phosphatidylethanolamine | 4.3 ± 0.2 | 18 ± 2 | 6.3 ± 0.3 | 5.3 ± 0.3 |
| Ceramide aminoethylphosphonate | 10 ± 1 | 24 ± 1 | 24.6 ± 0.4 | 22 ± 1 |
| Phosphatidylserine | 1.6 ± 0.9 | 4.0 ± 0.1 | 3.2 ± 0.4 | 5.7 ± 0.2 |
| Phosphatidylcholine | 74 ± 4 | 39.7 ± 0.4 | 53.2 ± 0.3 | 58.6 ± 0.6 |
| Lysophosphatidylcholine | 2.9 ± 0.3 | 3.8 ± 0.9 | 5.4 ± 0.5 | 3.3 ± 0.5 |
Seasonal levels of phospholipid fatty acids of Crassostrea gigas. ECLs (equivalent chain lengths) were determined using a CP-Sil 5 column CB. i, iso; ai, anteiso; br, branched.
| Fatty Acids (Symbol) | ECL a | Abundance (wt %) | |||
|---|---|---|---|---|---|
| Winter | Spring | Summer | Autumn | ||
| 14:0 | 14.00 | 1.05 ± 0.01 | 2.1 ± 0.1 | 1.46 ± 0.01 | 1.75 ± 0.04 |
| 4,8,12-Me3-13:0 | 14.49 | 0.3 ± 0.1 | 2.2 ± 0.1 | 1.73 ± 0.04 | 1.06 ± 0.04 |
| 15:0 | 15.00 | 1.2 ± 0.1 | 0.56 ± 0.09 | 0.61 ± 0.01 | 1.28 ± 0.01 |
| 15.60 | 0.5 ± 0.1 | * | 0.52 ± 0.02 | 0.44 ± 0.01 | |
| 16:0 | 16.00 | 14.6 ± 0.5 | 16.8 ± 0.06 | 23.8 ± 0.1 | 19.1 ± 0.3 |
| 16.64 | 1.08 ± 0.01 | 0.5 ± 0.03 | 1.24 ± 0.03 | 0.84 ± 0.01 | |
| 17:0 | 17.00 | 2.8 ± 0.4 | 1.41 ± 0.01 | 1.64 ± 0.03 | 2.4 ± 0.1 |
| 2-OH-16:0 | 17.18 | 1.6 ± 0.1 | 1.7 ± 0.1 | 0.9 ± 0.03 | 1.99 ± 0.07 |
| 17.64 | 0.36 ± 0.01 | 0.31 ± 0.01 | 0.88 ± 0.01 | 0.57 ± 0.02 | |
| 18:0 | 18.00 | 5 ± 0.1 | 5.6 ± 0.2 | 7.32 ± 0.03 | 5.8 ± 0.2 |
| 9-16:1 | 15.74 | 1.75 ± 0.01 | 1.9 ± 0.1 | 1.18 ± 0.02 | 3.16 ± 0.01 |
| 7-Me-6( | 16.20 | 0.32 ± 0.01 | n.d. | n.d. | 0.20 ± 0.01 |
| 7-Me-6( | 16.53 | 0.65 ± 0.01 | 0.22 ± 0.01 | 0.36 ± 0.03 | 0.42 ± 0.02 |
| 9-18:1 | 17.76 | 2.8 ± 0.1 | 0.94 ± 0.05 | 4.78 ± 0.04 | 2.41 ± 0.07 |
| 11-18:1 | 17.81 | 4.5 ± 0.1 | 5.8 ± 0.2 | 2.46 ± 0.03 | 5.72 ± 0.06 |
| 3-19:1 | 18.58 | 1.6 ± 0.1 | 1.53 ± 0.05 | 1.36 ± 0.01 | 2.5 ± 0.01 |
| 11-20:1 | 19.68 | 1.6 ± 0.1 | 3.34 ± 0.07 | 7.19 ± 0.03 | 2.94 ± 0.03 |
| 13-20:1 | 19.73 | 5.8 ± 0.2 | 5.43 ± 0.05 | 2.16 ± 0.01 | 5.8 ± 0.1 |
| 18:4 | 17.54 | 1.01 ± 0.01 | 0.9 ± 0.02 | 1.00 ± 0.01 | 0.9 ± 0.01 |
| 18:2 | 17.66 | 0.3 ± 0.1 | 0.84 ± 0.04 | 2.84 ± 0.05 | 0.67 ± 0.01 |
| 20:4 | 19.24 | 4.2 ± 0.1 | 2.07 ± 0.01 | 3.35 ± 0.04 | 3.67 ± 0.01 |
| 20:5 | 19.34 | 9.3 ± 0.1 | 14.5 ± 0.1 | 7.53 ± 0.03 | 9.54 ± 0.01 |
| 20:3 | 19.49 | 0.5 ± 0.01 | 0.73 ± 0.03 | 0.40 ± 0.01 | 0.45 ± 0.01 |
| 20:2 | 19.52 | 0.9 ± 0.1 | 1.28 ± 0.04 | 1.10 ± 0.01 | 1.06 ± 0.05 |
| 22:6 | 21.12 | 7.8 ± 0.2 | 5.51 ± 0.09 | 9.50 ± 0.03 | 7.72 ± 0.09 |
| 22:4 | 21.19 | 1.42 ±0.01 | 1.4 ± 0.05 | 2.36 ± 0.01 | 1.17 ± 0.06 |
| 22:5 | 21.28 | 0.38 ± 0.01 | 0.30 ± 0.01 | 0.45 ± 0.01 | 0.37 ± 0.01 |
| 22:2 | 21.40 | 1.31 ± 0.01 | 0.99 ± 0.01 | 1.98 ± 0.02 | 1.1 ± 0.01 |
| 22:2 | 21.46 | 9.6 ± 0.3 | 9.02 ± 0.13 | 4.74 ± 0.05 | 7.4 ± 0.2 |
| 16:0 | 16.48 | 0.68 ± 0.01 | 0.56 ± 0.08 | 0.25 ± 0.01 | 0.39 ± 0.02 |
| br-17:0 | 17.12 | 0.8 ± 0.1 | 0.39 ± 0.04 | 0.24 ± 0.01 | 0.28 ± 0.04 |
| br-17:0 | 17.22 | 0.25 ± 0.01 | * | 0.27 ± 0.01 | 0.2 ± 0.01 |
| 17:0 | 17.48 | 0.83 ± 0.01 | 0.59 ± 0.08 | * | 0.49 ± 0.07 |
| br-18:0 | 18.10 | 0.9 ± 0.1 | n.d. | n.d. | n.d. |
| br-18:0 | 18.22 | 0.82 ± 0.01 | 0.39 ± 0.02 | n.d. | 0.38 ± 0.03 |
| 18:0 | 18.48 | 6.6 ± 0.2 | 6 ± 2 | 1.49 ± 0.02 | 2.97 ± 0.03 |
| br-19:0 | 19.22 | 0.33 ± 0.01 | 0.19 ± 0.01 | * | 0.26 ± 0.02 |
| br-20:1 | 20.06 | 1 ± 0.1 | 0.42 ± 0.06 | * | 0.28 ± 0.06 |
| br-20:1 | 20.10 | 0.41 ± 0.01 | 0.37 ± 0.08 | 0.49 ± 0.01 | 0.59 ± 0.09 |
| 20:0 | 20.17 | 1.9 ± 0.2 | 1.66 ± 0.04 | 0.65 ± 0.02 | 0.63 ± 0.03 |
Minor FAs as traces (<0.2%) (ECL): i-15:0 (14.62); 4-16:1 (15.70); ai-17:0 (16.73); i-19:0 (18.61); ai-19:0 (18.72); br-20:0 (19.38); 21:2n-8,14 (19.91); 22:0 (22.00); 5-24:1 (23.27); 24:0 (24.00). Values are the means of three replicates (mean ± standard deviation. n.d., not detected, and * <0.2%).
Comparison between the present study and the literature for the major PUFAs.
| Species | EPA % TL FA | DHA % TL FA | NMI % TL FA | Country | References |
|---|---|---|---|---|---|
| 10.8–15.2 | 10.3–15.5 | - | Ireland | [ | |
| 16.4–25.5 | 15.6–21.3 | 3.9–7.7 | Germany | [ | |
| 17.9–19.7 | 19.7–35.8 | - | Brazil | [ | |
| 7.5–15.4 | 5.5–9.5 | 6.8–10.9 | France | Present study | |
| 13.8–22.4 | 9.9–17.6 | 3.3–7.3 | Spain | [ | |
| 12.3 in muscle | 17.3 in muscle | 4.1 in muscle | France | [ | |
| 18.6–21.7 in PC | 13.1–15.8 in PC | 2.7–3.5 in PC | France | [ | |
| 10.3–17.4 | 22.5–32.5 | 7.8–12.8 | Mexico | [ | |
| 7.6–17.4 | 8.2–18.5 | 2.8–13 | Spain | [ |
Seasonal composition of the total free sterols of Crassostrea gigas. X1, X2: unidentified sterols; Values are the mean of three replicates (mean ± s.d.); s.d., standard deviation; n.d., non detected. % phytosterols calculated with respect to total sterols.
| Systematic Names | Trivial Names | % Total Lipids | |||
|---|---|---|---|---|---|
| Winter | Spring | Summer | Autumn | ||
| 24- | 24- | 5.2 ± 0.1 | 5.65 ± 0.1 | 3.57 ± 0.05 | 4.9 ± 0.2 |
| 24- | 24- | 0.51 ± 0.06 | n.d. | 0.47 ± 0.02 | 0.7 ± 0.07 |
| Cholesta-5,22 | 22 | 1.7 ± 0.3 | 1.92 ± 0.08 | 0.9 ± 0.1 | 1.7 ± 0.2 |
| Cholesta-5,22 | 22 | 8.94 ± 0.07 | 6.3 ± 0.2 | 5.6 ± 0.1 | 7.5 ± 0.4 |
| 5α-Cholest-22 | 22-Dehydrocholestanol | 1.2 ± 0.2 | n.d. | 0.8 ± 0.2 | 1.4 ± 0.2 |
| Cholest-5-en-3β-ol | Cholesterol | 32.1 ± 0.7 | 35.8 ± 0.4 | 21.4 ± 0.3 | 30.3 ± 0.4 |
| 5α-Cholestan-3β-ol | Cholestanol | 3.94 ± 0.08 | 6.7 ± 0.7 | 4 ± 0.1 | 4.7 ± 0.2 |
| 24-Methylcholesta-5,22 | Brassicasterol/Crinosterol | 12.8 ± 0.7 | 12.6 ± 0.3 | 9.19 ± 0.05 | 10.7 ± 0.2 |
| 4α-Methyl-5α-cholest-7-en-3β-ol | Lophenol | 0.91 ± 0.08 | n.d. | n.d. | n.d. |
| X1 (Δ° C28:0) | -- | 0.5 ± 0.2 | n.d. | 1.71 ± 0.05 | n.d. |
| 24-Methylcholesta-5,24(28)-dien-3β-ol | 24-Methylenecholesterol | 14 ± 0.2 | 12.9 ± 0.5 | 8.35 ± 0.03 | 10.7 ± 0.1 |
| 24-Methylcholest-5-en-3β-ol | Campesterol/22,23-Dihydrobrassicasterol | 6.24 ± 0.07 | 6.93 ± 0.03 | 6 ± 0.1 | 5.5 ± 0.1 |
| 5α-24-Ethylcholest-25-en-3β-ol | 5α-Poriferast-25-en-3β-ol/25-Dehydroporiferastanol | 0.53 ± 0.07 | n.d. | n.d. | n.d. |
| 5α-24-Ethylcholesta-22,24(25)-dien-3β-ol | 5α-Porifera-22,24(25)-dien-3β-ol | 1.2 ± 0.1 | n.d. | 1.11 ± 0.01 | 1.1 ± 0.2 |
| 24-Ethylcholest-5,22 | Poriferasterol/Stigmasterol | 1.78 ± 0.03 | 1.7 ± 0.2 | 1.67 ± 0.04 | 1.7 ± 0.1 |
| 4,24-Dimethylcholesta-5,7,24(28)-trien-3β-ol | 4-Methyl-5α-Ergosta-24(28)-en-3β-ol | 0.4 ± 0.03 | n.d. | 7.8 ± 0.1 | 5.6 ± 0.3 |
| 24-Ethylcholest-5-en-3β-ol | β-Sitosterol/Clionasterol | 5.4 ±0.3 | 9.9 ± 0.5 | 10.2 ± 0.2 | 6.0 ± 0.4 |
| 24-Ethyl-5α-cholest-22 | Poriferastanol/Stigmastanol | 2.8 ± 0.2 | 2.6 ± 0.2 | 1.6 ± 0.2 | 3.5 ± 0.2 |
| 24-Ethylcholesta-5,24(28)-dien-3β-ol | Fucosterol | n.d. | n.d. | 1.23 ± 0.04 | 0.65 ± 0.04 |
| 4-Methyl-24-ethyl-5α-cholesta-7-en-3β-ol | 4-Methyl-5α-Porifera-7-en-3β-ol/24-Ethyllophenol | n.d. | n.d. | 2.90 ± 0.05 | 0.96 ± 0.08 |
| X2 (Δ° C30:0) | -- | n.d. | n.d. | 0.95 ± 0.04 | n.d. |
| 4-Methyl-24-ethyl-cholesta-5-en-3β-ol | 4-Methyl-Porifera-5-en-3β-ol | n.d. | n.d. | 0.73 ± 0.09 | 0.61 ± 0.09 |
| % Phytosterols | 30.8 | 33.7 | 33.4 | 30.1 | |
Potential economic, nutritional, and health benefits of C. gigas lipids.
| Lipids | Potential Benefits | References |
|---|---|---|
| Lecithin (with associated PUFAs) | Protection against colon cancer | [ |
| Treatment of psoriasis | [ | |
| High-quality source for food industry | [ | |
| CAEP | Implication in some haemocyte functions | [ |
| Cardiolipin | Optimization of mitochondrial respiratory | [ |
| performance | [ | |
| Improve efficacy and tolerability of cancer chemotherapy | [ | |
| Cancer prevention | [ | |
| Neuroprotective efficacy | [ | |
| Cardiovascular disease protection | [ | |
| Improvement of some obesity-associated metabolic syndrome features (Type 2 diabetes) | [ | |
| Anti-inflammatory effect | [ | |
| Diunsaturated NMI FAs | Resistance to oxidative stress and microbial lipases | [ |
| Plasmalogens | Countering oxidative stress | [ |
| Phytosterols | Cholesterol-lowering action | [ |
| Reduction in cardiovascular risk | [ | |
| Anti-inflammatory effect | [ |